ClinicalTrials.Veeva

Menu

Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women

University of Minnesota (UMN) logo

University of Minnesota (UMN)

Status

Enrolling

Conditions

Hypertension
Menopause, Premature
Menopause
Blood Pressure

Treatments

Diagnostic Test: Sympathoexcitatory Maneuvers
Diagnostic Test: Baroreflex sensitivity testing
Diagnostic Test: Microneurography to measure muscle sympathetic nerve activity (MSNA)
Diagnostic Test: Blood tests

Study type

Observational

Funder types

Other

Identifiers

NCT04439370
PT-2018-27097

Details and patient eligibility

About

This is a cross-sectional study in which the investigators will determine the impact of premature/early menopause on MSNA, BP and baroreflex sensitivity in younger (≤49 yr old) and older (≥50 yr old) women. Specifically, aim one will determine mechanisms driving autonomic dysregulation of BP in premature and early menopausal women and aim two will determine mechanisms driving autonomic dysregulation of BP in older menopausal women. The study design outlined below will permit testing of aim one and aim two.

Full description

Aim One: Determine mechanisms driving autonomic dysregulation of blood pressure (BP) in premature and early menopausal women. Because sympathetic activity and baroreflex function are important contributors for autonomic support of BP regulation, these two mechanisms will be assessed in premature and early menopausal women who are ≤49 yr old. To specifically identify the influence of menopause, these women will be compared to age-matched premenopausal women. The primary hypothesis is that there is greater resting sympathetic activity and blunted baroreflex function in premature and early menopausal women compared with age-matched premenopausal women. The secondary hypothesis is that BP and sympathetic reactivity will be greater in premature and early menopausal compared with age-matched premenopausal women when the sympathetic nervous system is challenged with a stressor.

Aim Two: Determine mechanisms driving autonomic dysregulation of BP in older menopausal women. Because older age contributes to risk of CVD, it is imperative to assess the long-term effects of premature and early menopause in older (≥50 yr) women. To determine the impact of the premature loss of sex hormones on cardiovascular physiology, women whom have lived without functioning ovaries for >10 yr will be compared to age-matched women who entered menopause at a typical age. The primary hypothesis is that resting sympathetic activity is greater and baroreflex function is attenuated in women who experience premature or early menopause compared with typically-aged menopausal women. The secondary hypothesis is that BP and sympathetic reactivity will be greater in premature and early compared with typically-aged menopausal women when the sympathetic nervous system is challenged with a stressor.

Enrollment

160 estimated patients

Sex

Female

Ages

35 to 70 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Aged 35-49 or 50-70 years of age who experienced premature (<40) or early (≤45) menopause
  • Premenopausal 35-49 years of age
  • Typical-age menopause (i.e., after 45 years of age), who are between 50-70 years old
  • Menopause will be confirmed by subject report of amenorrhea for 12 months and serum FSH of >30 mIU/mL

Exclusion criteria

  • Current nicotine/tobacco use within the past six months
  • Are diabetic or asthmatic
  • Have diagnosed significant carotid stenosis
  • Have a history of significant autonomic dysfunction, heart disease, respiratory disease or a severe neurologic condition such as stroke or traumatic brain injury.
  • Have existing metabolic or endocrine abnormities
  • Take any heart/blood pressure medications that are determined to interfere with study outcomes
  • IF the participant is premenopausal AND currently taking OC or other exogenous steroids that are determined to interfere with study outcomes
  • Females who classify as having early or premature menopause AND are not willing to discontinue OC or MHT in order to complete the study
  • Are pregnant or breastfeeding

Trial design

160 participants in 4 patient groups

Aim 1: Postmenopausal Women
Description:
Participants in this group are postmenopausal women.
Treatment:
Diagnostic Test: Blood tests
Diagnostic Test: Microneurography to measure muscle sympathetic nerve activity (MSNA)
Diagnostic Test: Baroreflex sensitivity testing
Diagnostic Test: Sympathoexcitatory Maneuvers
Aim 1: Premenopausal Women
Description:
Participants in this group are premenopausal women.
Treatment:
Diagnostic Test: Blood tests
Diagnostic Test: Microneurography to measure muscle sympathetic nerve activity (MSNA)
Diagnostic Test: Baroreflex sensitivity testing
Diagnostic Test: Sympathoexcitatory Maneuvers
Aim 2: Premature/Early Menopause
Description:
Participants in this group women who experienced premature or early menopause.
Treatment:
Diagnostic Test: Blood tests
Diagnostic Test: Microneurography to measure muscle sympathetic nerve activity (MSNA)
Diagnostic Test: Baroreflex sensitivity testing
Diagnostic Test: Sympathoexcitatory Maneuvers
Aim 2: Typical-Age Menopause
Description:
Participants in this group are women who experienced menopause at a typical age.
Treatment:
Diagnostic Test: Blood tests
Diagnostic Test: Microneurography to measure muscle sympathetic nerve activity (MSNA)
Diagnostic Test: Baroreflex sensitivity testing
Diagnostic Test: Sympathoexcitatory Maneuvers

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Manda Keller-Ross, PhD, DPT, PT

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems